FIELD: medical biotechnology and immunology.
SUBSTANCE: vaccine against COVID-19 and a method of its preparation by cultivating the viral strain nCoV-19/Russia/SP48-1339/2021 of SARS-Cov-2 virus deposited in a specialized collection of reference cultures of strains of pathogenicity groups II–IV (arboviruses and others) are described. FSBI "48 Central Research Institute" of the Russian Ministry of Defense under registration No. 1339, with subsequent inactivation and purification of the vaccine antigen.
EFFECT: increase in the degree of purification of the viral antigen of the SARS-Cov-2 virus. The use of a highly virulent strain, highly pathogenic for humans, ensures high immunogenicity and effectiveness of the vaccine, and the use of a highly purified vaccine preparation based on a viral antigen reduces the risks of unwanted side effects by increasing the degree of its purification.
7 cl, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
| METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| AGENT FOR SPECIFIC PREVENTION OF COVID-19 FOR CARNIVORES | 2021 |
|
RU2768749C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| METHOD OF OBTAINING RECOMBINANT ANTIGEN MBP_RBD_6HIS OF SARS-CoV-2 VIRUS WITH C-TERMINAL AFFINITY TAG 6XHIS-TAG, INTENDED FOR USE AS COMPONENT OF REAGENT KIT FOR COVID-19 SERODIAGNOSTICS | 2023 |
|
RU2813324C1 |
| VIRUS-LIKE PARTICLES (VLP) VACCINE FOR PREVENTION OF COVID-19 FOR INTRANASAL USE | 2024 |
|
RU2828323C1 |
